
Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFB6TmQwQ0RRVngtLUx5MjMya1lFTHRQY1ZPUF90bWhNQmxHMHBGUHE2U2dnQUNSU011dUR3bTFwWHUwY0JtQk5jalVlOUZTWHJJUWtsSVJJbjVodHBiTjdYaEJ6Njhyb0U?oc=5" target="_blank">Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114</a>&nbsp;&nbsp;<font color="#6f6f6f">Science | AAAS</font>

